looking back at the announcement from 27th Nov 2019 and 23rd April 2020 regarding treatment of mrsa infection in burn model it seems we already showed greater bacteria killing effect and wound healing than soframycin at once daily application compared to twice daily for soframycin. If these results are repeated in human trials, and hard to imagine why they should be any different, then that will be big news surely. I would be very nervous if I was not a holder and just waiting for share price to drop so I could buy in. If I understand this correctly our product is more effective than a currently marketed product when applied once a day as opposed to twice daily for current go to product in previous animal trials.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)